MX2010011845A - Agonistas del receptor y2 y/o y4 de larga accion. - Google Patents

Agonistas del receptor y2 y/o y4 de larga accion.

Info

Publication number
MX2010011845A
MX2010011845A MX2010011845A MX2010011845A MX2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A
Authority
MX
Mexico
Prior art keywords
ethoxy
seq
carboxy
acid
acetyl
Prior art date
Application number
MX2010011845A
Other languages
English (en)
Spanish (es)
Inventor
Soeren Oestergaard
Sanne Moeller Knudsen
Jane Spetzler
Rasmus Joergensen
Jacob Kofoed
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2010011845A publication Critical patent/MX2010011845A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010011845A 2008-05-16 2009-05-18 Agonistas del receptor y2 y/o y4 de larga accion. MX2010011845A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP09154461 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (1)

Publication Number Publication Date
MX2010011845A true MX2010011845A (es) 2010-11-22

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011845A MX2010011845A (es) 2008-05-16 2009-05-18 Agonistas del receptor y2 y/o y4 de larga accion.

Country Status (12)

Country Link
US (1) US20110275559A1 (https=)
EP (1) EP2279204A1 (https=)
JP (1) JP2011520847A (https=)
KR (1) KR20110017874A (https=)
CN (1) CN102027007A (https=)
AU (1) AU2009248041B2 (https=)
BR (1) BRPI0912615A2 (https=)
CA (1) CA2723855A1 (https=)
IL (1) IL208836A0 (https=)
MX (1) MX2010011845A (https=)
RU (1) RU2504550C2 (https=)
WO (1) WO2009138511A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2600887A4 (en) 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE Y RECEPTOR AGONISTS
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
DK3068421T3 (da) * 2013-11-15 2019-06-24 Novo Nordisk As Selektive pyy-forbindelser og anvendelser deraf
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
US10610807B2 (en) 2014-01-17 2020-04-07 Repligen Corporation Sterilizing chromatography columns
CN114805527A (zh) * 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
AU2021257477A1 (en) * 2020-04-17 2022-12-08 I2O Therapeutics, Inc. Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273713B2 (en) * 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
CA2560174A1 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
MXPA06015049A (es) * 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
AU2006271792A1 (en) * 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity

Also Published As

Publication number Publication date
BRPI0912615A2 (pt) 2016-01-26
CA2723855A1 (en) 2009-11-19
EP2279204A1 (en) 2011-02-02
RU2010149474A (ru) 2012-06-27
RU2504550C2 (ru) 2014-01-20
WO2009138511A1 (en) 2009-11-19
JP2011520847A (ja) 2011-07-21
CN102027007A (zh) 2011-04-20
KR20110017874A (ko) 2011-02-22
AU2009248041B2 (en) 2013-10-03
IL208836A0 (en) 2011-01-31
AU2009248041A1 (en) 2009-11-19
US20110275559A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
MX2010011845A (es) Agonistas del receptor y2 y/o y4 de larga accion.
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
EP2190873B1 (en) Truncated glp-1 derivatives and their therapeutical use
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
US20130040877A1 (en) Long-acting y2 receptor agonists
EP2190460A1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal